INTRODUCTION: Mirasol Pathogen Reduction Technology (PRT) treatment uses riboflavin and UV light to inactivate pathogens in blood components. Neutrophil [polymorphonuclear cells (PMN)] priming activity accumulates during routine storage of cellular blood components, and this activity has been implicated in transfusion-related acute lung injury (TRALI). We hypothesize that PRT-treatment of blood components affects the priming activity generated during storage of packed RBCs (PRBCs) or platelet concentrates (PCs), which can elicit ALI in vivo. METHODS: Plasma, PRBCs and PCs were isolated from healthy donor's whole blood or by apheresis. Half of a collected unit was treated with PRT treatment and the remainder was left as an unmodified control. Supernatant was collected during storage of PCs and PRBCs and assayed for PMN priming activity and used as the second event in a two-event in vivo model of TRALI. RESULTS: PRT treatment did not induce priming activity in plasma or affect the priming activity generated during storage of PCs or PRBCs as compared with the unmodified controls. The supernatants from stored, but not fresh, PCs and PRBCs did cause ALI as the second event in a two-event animal model of TRALI, which was unaffected by PRT treatment. We conclude that the PRT treatment does not induce priming activity in plasma nor does it affect the priming activity generated during storage of PCs or PRBCs or their ability to cause ALI as the second event in a two-event in vivo model of TRALI. Moreover, the amount of priming activity in TRIMA-isolated PCs was significantly less than SPECTRA-isolated PCs.
INTRODUCTION: Mirasol Pathogen Reduction Technology (PRT) treatment uses riboflavin and UV light to inactivate pathogens in blood components. Neutrophil [polymorphonuclear cells (PMN)] priming activity accumulates during routine storage of cellular blood components, and this activity has been implicated in transfusion-related acute lung injury (TRALI). We hypothesize that PRT-treatment of blood components affects the priming activity generated during storage of packed RBCs (PRBCs) or platelet concentrates (PCs), which can elicit ALI in vivo. METHODS: Plasma, PRBCs and PCs were isolated from healthy donor's whole blood or by apheresis. Half of a collected unit was treated with PRT treatment and the remainder was left as an unmodified control. Supernatant was collected during storage of PCs and PRBCs and assayed for PMN priming activity and used as the second event in a two-event in vivo model of TRALI. RESULTS: PRT treatment did not induce priming activity in plasma or affect the priming activity generated during storage of PCs or PRBCs as compared with the unmodified controls. The supernatants from stored, but not fresh, PCs and PRBCs did cause ALI as the second event in a two-event animal model of TRALI, which was unaffected by PRT treatment. We conclude that the PRT treatment does not induce priming activity in plasma nor does it affect the priming activity generated during storage of PCs or PRBCs or their ability to cause ALI as the second event in a two-event in vivo model of TRALI. Moreover, the amount of priming activity in TRIMA-isolated PCs was significantly less than SPECTRA-isolated PCs.
Authors: Christopher C Silliman; A Jason Bjornsen; Travis H Wyman; Marguerite Kelher; Jenny Allard; Sarah Bieber; Norbert F Voelkel Journal: Transfusion Date: 2003-05 Impact factor: 3.157
Authors: Christopher C Silliman; David J Elzi; Daniel R Ambruso; Rene J Musters; Christine Hamiel; Ronald J Harbeck; Andrew J Paterson; A Jason Bjornsen; Travis H Wyman; Marguerite Kelher; Kelly M England; Nathan McLaughlin-Malaxecheberria; Carlton C Barnett; Junichi Aiboshi; Anirban Bannerjee Journal: J Leukoc Biol Date: 2003-04 Impact factor: 4.962
Authors: Marguerite R Kelher; Tomhiko Masuno; Ernest E Moore; Sagar Damle; Xianzhong Meng; Yong Song; Xiayuan Liang; Jerry Niedzinski; Steven S Geier; Samina Y Khan; Fabia Gamboni-Robertson; Christopher C Silliman Journal: Blood Date: 2009-01-08 Impact factor: 22.113
Authors: Patrick H Ruane; Richard Edrich; Deanna Gampp; Shawn D Keil; R Lynne Leonard; Raymond P Goodrich Journal: Transfusion Date: 2004-06 Impact factor: 3.157
Authors: Christopher C Silliman; Ernest E Moore; Marguerite R Kelher; Samina Y Khan; Lauren Gellar; David J Elzi Journal: Transfusion Date: 2011-05-26 Impact factor: 3.157
Authors: Martin Hermann; Oliver Nussbaumer; Ralf Knöfler; Paul Hengster; Walter Nussbaumer; Werner Streif Journal: Transfus Med Hemother Date: 2010-09-15 Impact factor: 3.747
Authors: Christopher C Silliman; Marguerite R Kelher; Samina Y Khan; F Bernadette West; Nathan J D McLaughlin; David J Elzi; Kelly England; Jason Bjornsen; Susan A Kuldanek; Anirban Banerjee Journal: Transfusion Date: 2017-09-06 Impact factor: 3.157
Authors: John-Paul Tung; John F Fraser; Maria Nataatmadja; Kathryn I Colebourne; Adrian G Barnett; Kristen M Glenister; Anna Y Zhou; Peter Wood; Christopher C Silliman; Yoke L Fung Journal: Crit Care Date: 2012-02-01 Impact factor: 9.097